0001209191-19-053072.txt : 20191015
0001209191-19-053072.hdr.sgml : 20191015
20191015064254
ACCESSION NUMBER: 0001209191-19-053072
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20191002
FILED AS OF DATE: 20191015
DATE AS OF CHANGE: 20191015
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Drape Eric
CENTRAL INDEX KEY: 0001790905
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-16174
FILM NUMBER: 191149026
MAIL ADDRESS:
STREET 1: C/O TEVA, 5 BASEL STREET, P.O. BOX 3190
CITY: PETACH TIKVA
STATE: L3
ZIP: 4951033
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: TEVA PHARMACEUTICAL INDUSTRIES LTD
CENTRAL INDEX KEY: 0000818686
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L3
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 5 BAZEL ST
STREET 2: P O B 3190
CITY: PETACH TIKVA
STATE: L3
ZIP: 49131
BUSINESS PHONE: 9729267267
MAIL ADDRESS:
STREET 1: TEVA PHARMACEUTICAL INDUSTRIES LIMITED
STREET 2: 5 BAZEL ST PO B 3190
CITY: PETACH TIKVA
STATE: L3
ZIP: 49131
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2019-10-02
0
0000818686
TEVA PHARMACEUTICAL INDUSTRIES LTD
TEVA
0001790905
Drape Eric
C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.
5 BASEL STREET
PETACH TIKVA
L3
4951033
ISRAEL
0
1
0
0
Executive VP Global Operations
Ordinary Shares
17195
D
Stock Options (right to buy)
40.15
2023-12-09
Ordinary Shares
25005
D
Stock Options (right to buy)
48.76
2024-03-11
Ordinary Shares
15002
D
Stock Options (right to buy)
57.35
2025-02-11
Ordinary Shares
54623
D
Stock Options (right to buy)
55.75
2026-02-11
Ordinary Shares
54950
D
Stock Options (right to buy)
34.90
2027-02-14
Ordinary Shares
62364
D
Stock Options (right to buy)
16.99
2027-09-18
Ordinary Shares
33339
D
Stock Options (right to buy)
18.61
2028-02-08
Ordinary Shares
50231
D
Restricted Share Units
Ordinary Shares
7852
D
Restricted Share Units
Ordinary Shares
19702
D
Restricted Share Units
Ordinary Shares
35820
D
The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Stock options were granted on December 9, 2013, with 8,335 having vested on each of December 9, 2015, December 9, 2016 and December 9, 2017.
Stock options were granted on March 12, 2014, with 5,000 having vested on each of March 12, 2015 and March 12, 2016 and 5,002 having vested on March 12, 2017.
Stock options were granted on February 12, 2015, with 18,207 having vested on each of February 12, 2017 and February 12, 2018 and 18,209 on February 12, 2019.
Stock options were granted on February 12, 2016, with 18,316 having vested on each of February 12, 2018 and February 12, 2019 and 18,318 vesting on February 12, 2020.
Stock options were granted on February 14, 2017, with 20,788 having vested on February 14, 2019, and 20,788 vesting on each of February 14, 2020 and February 14, 2021.
Stock options were granted on September 18, 2017 and vested on September 18, 2019.
Stock options were granted on February 9, 2018, with 16,743 vesting on each of February 9, 2020 and February 9, 2021 and 16,745 vesting on February 9, 2022.
Restricted share units were granted on February 14, 2017, with 3,926 vesting on each of February 14, 2020 and February 14, 2021.
Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
Restricted share units were granted on February 9, 2018, with 6,567 vesting on each of February 9, 2020 and February 9, 2021 and 6,568 vesting on February 9, 2022.
Restricted share units were granted on March 4, 2019, with 11,940 vesting on each of March 4, 2021, March 4, 2022 and March 4, 2023.
/s/ Dov Bergwerk, as attorney-in-fact for Eric Drape
2019-10-15
EX-24.3_875926
2
poa.txt
POA DOCUMENT
POWER OF ATTORNEY
FOR SECTION 16 REPORTING OBLIGATIONS
KNOW ALL BY THESE PRESENTS, that the undersigned hereby makes, constitutes and
appoints Dov Bergwerk, Dikla Tadmor, Netanel Derovan and Shira Aran-Porat
signing singly, as the undersigned's true and lawful attorney-in-fact, with full
power and authority as hereinafter described on behalf of and in the name, place
and stead of the undersigned to:
(1) prepare, execute, acknowledge, deliver and file Forms 3, 4, and 5 (including
any amendments thereto) with respect to the securities of Teva Pharmaceutical
Industries Limited, a company incorporated under the law of Israel, or any
successor thereto (the "Company"), with the U.S. Securities and Exchange
Commission, any national securities exchanges and the Company, as considered
necessary or advisable under Section 16(a) of the Securities Exchange Act of
1934 and the rules and regulations promulgated thereunder, as amended from time
to time (the "Exchange Act");
(2) seek or obtain, as the undersigned's representative and on the undersigned's
behalf, information of transactions in the Company's securities from any
third-party, including brokers, employee benefit plan administrators and
trustees, and the undersigned hereby authorizes any such person to release any
such information to the undersigned and approves and ratifies any such release
of information; and
(3) perform any and all other acts which in the discretion of such
attorney-in-fact is necessary or desirable for and on behalf of the undersigned
in connection with the foregoing.
The undersigned acknowledges that:
(1) this Power of Attorney authorizes, but does not require, such
attorney-in-fact to act in his or her discretion on information provided to such
attorney-in-fact without independent verification of such information;
(2) any documents prepared, executed, acknowledged and/or delivered by such
attorney-in-fact on behalf of the undersigned pursuant to this Power of Attorney
will be in such form and will contain such information and disclosure as such
attorney-in-fact, in his or her discretion, deems necessary or desirable;
(3) neither the Company nor such attorney-in-fact assumes (i) any liability for
the undersigned's responsibility to comply with the requirement of the Exchange
Act, (ii) any liability of the undersigned for any failure to comply with such
requirements or (iii) any obligation or liability of the undersigned for profit
disgorgement under Section 16(b) of the Exchange Act; and
(4) this Power of Attorney does not relieve the undersigned from responsibility
for compliance with the undersigned's obligations under the Exchange Act,
including without limitation the reporting requirements under Section 16 of the
Exchange Act.
The undersigned hereby gives and grants the foregoing attorney-in-fact full
power and authority to do and perform all and every act and thing whatsoever
requisite, necessary or appropriate to be done in and about the foregoing
matters as fully to all intents and purposes as the undersigned might or could
do if present, hereby ratifying all that such attorney-in-fact of, for and on
behalf of the undersigned, shall lawfully do or cause to be done by virtue of
this Power of Attorney.
This Power of Attorney shall remain in full force and effect until revoked by
the undersigned in a signed writing delivered to such attorney-in-fact.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be
executed as of this 7th day of October, 2019.
By: /s/ Eric Drape
Name: Eric Drape
Title: Executive VP, Global Operations